Author Archive

Social Network Analysis of Pharmaceutical Innovation

I was just notified of a fascinating paper citing my research from DrugPatentWatch.com. Briefly, I found two surprising results: Firstly, pharmaceutical innovation has been essentially immobile — it remains almost completely rooted in the United States and Western Europe. Secondly, there is virtually no innovation coming out of so-called emerging economies such as India and China (i.e. <1% as […]


Biotechnology in Countries Starting with “I” – Part 7: India

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. For the next chapter in this continuing series, let’s turn back to India and the draft National IPR Policy currently under debate in New Delhi. A great deal […]


New CMS Guidance for Biotech Industry On Coverage With Evidence Development: It’s All About The Outcomes

This is a guest post from Robert E. Wanerman, a member of Epstein Becker Green’s Health Care and Life Sciences practice. Do you have a response to Robert’s post? Respond in the comments section below. For many biotech manufacturers, obtaining Medicare coverage is a significant milestone in commercializing an item or service. Although Medicare coverage […]


New Years Bio-Pharmaceutical Resolution To Nurture MSME Innovation

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. At the start of a bright and shiny new year in 2015, I am thinking about my own New Years resolutions as well as one that I would […]


PatentDrop.com posts public-domain inventions

Patents require regular ‘maintenance’ payments to keep them in force. Because the cost of maintaining large patent portfolios can be substantial, many companies elect to abandon patents that they feel are not worth pursuing. Sometimes these patents are abandoned because they are outside a company’s focus, and in other cases they may represent markets too small for […]


Unlocking the Mystery of Angel Investment

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. In the “Mystery of Capital,” Peruvian economist Hernando de Soto famously writes about the need to convert assets into capital for creation of social and economic value in […]


More on The Success Matrix

Gerry Langeler, author of The Success Matrix and Managing Director with OVP Venture Partners recently spoke at a breakfast event and was kind enough to record the video. Gerry’s thoughts on ‘Why scientists fail as entrepreneurs‘ was previously featured on the BiotechBlog, and his video is posted below. For more, you can also visit Gerry’s website at www.thesuccessmatrix.com.  


Key Elements of Succession Planning In Bioscience

This is a guest post from Steve McLaughlin, Managing Partner and Founder of US BioSearch. Do you have a response to Steve’s post? Respond in the comments section below. Effective succession plans involve a combination of many choices and decisions that are distinctive to each, specific company. Bioscience companies also present their own, unique challenges, as […]


Building Biotechnology in Poland

I will be presenting at Bioinnovation 2014 in Gdansk, Poland on October 20-21st. My talk will cover entrepreneurship and business development guidance from my textbook, Building Biotechnology and global competitiveness considerations from my global biotechnology ranking for Scientific American Worldview. I look forward to meeting European and Polish biotechnology practitioners, and learning more about biotechnology […]